Skip to main content
Erschienen in: Hepatology International 2/2009

01.06.2009 | Case Report

Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation

verfasst von: Soo Ryang Kim, Susumu Imoto, Taisuke Nakajima, Kenji Ando, Keiji Mita, Miyuki Taniguchi, Noriko Sasase, Toshiyuki Matsuoka, Masatoshi Kudo, Yoshitake Hayashi

Erschienen in: Hepatology International | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

We describe three cases of well-differentiated hepatocellular carcinoma (HCC) smaller than 15 mm in diameter completely eradicated with percutaneous ethanol injection (PEI) instead of using radiofrequency ablation (RFA). Ultrasound (US) examination revealed one nodule each in segment 2 (hypoechoic, near bile ducts, 10 mm), in segment 5 (hyperechoic, near the gall bladder, 15 mm), and in segment 7 (hypoechoic, near the diaphragm, 15 mm). Although imaging studies revealed isovascular (case 1) and hypervascular (cases 2 and 3) nodules, histological analysis of US-guided biopsy tissue revealed well-differentiated HCC. In consideration of the location of the nodules, PEI, instead of RFA, was administered and the nodules were rendered necrotic. Although RFA is superior to PEI in the treatment of small HCCs from the viewpoint of treatment response and long survival, PEI is strongly recommended for HCCs located near bile ducts, the gall bladder, and the diaphragm, especially when the nodules are smaller than 15 mm in diameter.
Literatur
1.
Zurück zum Zitat Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef
2.
Zurück zum Zitat Okuda K, Peteres RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984;54:2165–2173PubMedCrossRef Okuda K, Peteres RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984;54:2165–2173PubMedCrossRef
3.
Zurück zum Zitat Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557–1563PubMedCrossRef Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557–1563PubMedCrossRef
5.
Zurück zum Zitat Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–661PubMed Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–661PubMed
6.
Zurück zum Zitat Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130PubMedCrossRef Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130PubMedCrossRef
7.
Zurück zum Zitat Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004;127:1714–1723PubMedCrossRef Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004;127:1714–1723PubMedCrossRef
8.
Zurück zum Zitat Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapy. Hepatology 2009;49:453–459PubMedCrossRef Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapy. Hepatology 2009;49:453–459PubMedCrossRef
9.
Zurück zum Zitat Kasugai H, Osaki Y, Oka H, Kudo M, Seki T, Osaka Liver Cancer Study Group. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. Oncology 2007;72:S72–S75CrossRef Kasugai H, Osaki Y, Oka H, Kudo M, Seki T, Osaka Liver Cancer Study Group. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. Oncology 2007;72:S72–S75CrossRef
10.
Zurück zum Zitat Takeuchi H, Arata T, Takehara K, Shigeyasu K, Kanazawa T, Murata H, et al. A patient who developed diaphragmatic hernia one year after percutaneous radiofrequency ablation for hepatocellular carcinoma. Kanzo 2007;48:458–462CrossRef Takeuchi H, Arata T, Takehara K, Shigeyasu K, Kanazawa T, Murata H, et al. A patient who developed diaphragmatic hernia one year after percutaneous radiofrequency ablation for hepatocellular carcinoma. Kanzo 2007;48:458–462CrossRef
11.
Zurück zum Zitat Tomonaga C, Kawano A, Taguchi Y, Matsunaga T, Maruyama T, Toyoshima S, et al. Two cases of diaphragmatic hernia following percutaneous radiofrequency ablation of hepatocellular carcinoma. Kanzo 2007;48:529–537CrossRef Tomonaga C, Kawano A, Taguchi Y, Matsunaga T, Maruyama T, Toyoshima S, et al. Two cases of diaphragmatic hernia following percutaneous radiofrequency ablation of hepatocellular carcinoma. Kanzo 2007;48:529–537CrossRef
12.
Zurück zum Zitat Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987;60:810–819PubMedCrossRef Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987;60:810–819PubMedCrossRef
13.
Zurück zum Zitat Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101–105PubMed Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101–105PubMed
14.
Zurück zum Zitat Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999;19:287–296PubMedCrossRef Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999;19:287–296PubMedCrossRef
15.
Zurück zum Zitat Kondo Y, Niwa Y, Akikusa B, Takazawa H, Okabayashi A. A histopathologic study of early hepatocellular carcinoma. Cancer 1983;52:687–692PubMedCrossRef Kondo Y, Niwa Y, Akikusa B, Takazawa H, Okabayashi A. A histopathologic study of early hepatocellular carcinoma. Cancer 1983;52:687–692PubMedCrossRef
16.
Zurück zum Zitat Nakashima T, Kojiro M. Hepatocellular Carcinoma: An Atlas of its Pathology. Tokyo: Springer-Verlag; 1987 Nakashima T, Kojiro M. Hepatocellular Carcinoma: An Atlas of its Pathology. Tokyo: Springer-Verlag; 1987
17.
Zurück zum Zitat Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353–357PubMedCrossRef Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353–357PubMedCrossRef
18.
Zurück zum Zitat Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In Tabor E, editor. Viruses and Liver Cancer. Amsterdam: Elsevier; 2002. 113–122CrossRef Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In Tabor E, editor. Viruses and Liver Cancer. Amsterdam: Elsevier; 2002. 113–122CrossRef
19.
Zurück zum Zitat Kojiro M. Pathology of Hepatocellular Carcinoma. Oxford: Blackwell; 2006. 39–49 Kojiro M. Pathology of Hepatocellular Carcinoma. Oxford: Blackwell; 2006. 39–49
20.
Zurück zum Zitat Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008;14:1997–2002PubMedCrossRef Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008;14:1997–2002PubMedCrossRef
Metadaten
Titel
Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation
verfasst von
Soo Ryang Kim
Susumu Imoto
Taisuke Nakajima
Kenji Ando
Keiji Mita
Miyuki Taniguchi
Noriko Sasase
Toshiyuki Matsuoka
Masatoshi Kudo
Yoshitake Hayashi
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9128-z

Weitere Artikel der Ausgabe 2/2009

Hepatology International 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.